Lipitor's Patent Cliff Timeline
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol, held U.S. patent protection until November 30, 2011. Generic entry began immediately after, with Ranbaxy Laboratories launching first via an authorized generic, followed by others like Watson and Mylan. This triggered rapid market erosion for the branded product.[1][2]
Immediate Drop in Pfizer's Market Share
Within the first year post-expiry, Lipitor's U.S. market share fell from nearly 100% to under 20%. By mid-2012, generics captured over 80% of prescriptions, driven by lower prices—generics launched at 80-90% discounts. Pfizer's global sales dropped from $125 billion peak (2006) to $4.4 billion by 2012, a 96% decline over five years.[1][3]
Why Generics Took Over So Fast
High generic penetration stemmed from:
- Pricing pressure: Retail prices for a 30-day generic supply fell to $10-15 vs. $150+ for branded Lipitor.
- Physician and payer switching: CVS Caremark and other PBMs favored generics; 90% of new scripts went generic within months.
- No pediatric exclusivity extension: Pfizer's 6-month extension ended in 2011, unlike some drugs.[2][4]
| Year | Branded Share (U.S. Rx) | Generic Share |
|------|--------------------------|---------------|
| 2010 | 95% | 5% |
| 2011 (pre-expiry) | 90% | 10% |
| 2012 | 15% | 85% |
| 2013 | 5% | 95% |[3]
Pfizer's Strategies to Slow the Loss
Pfizer countered with:
- Authorized generic: Partnered with Ranbaxy to capture some volume at lower prices.
- Copay cards and direct-to-consumer ads: Spent $100M+ in 2012 on marketing, retaining ~10% loyalists.
- Lawsuits: Delayed some generics via Hatch-Waxman challenges, but core patent expired cleanly.[2][5]
These delayed total wipeout but couldn't halt the 90%+ share loss by 2014.
Long-Term Market Impact
Lipitor's U.S. prescription volume stayed stable at ~20 million annually, but revenue shifted to generics. Pfizer pivoted to new drugs like Eliquis; the episode cost $20B+ in lost sales but freed resources. Globally, shares lingered longer in markets like Japan (expiry 2013).[1][3]
Lessons for Other Blockbusters
Lipitor exemplified the "patent cliff"—similar drops hit Nexium (80% share loss in 2014) and Singulair (90% in 2012). Biosimilars face slower erosion due to complexity, but small-molecule generics like Lipitor show 80-95% share transfer within 1-2 years.[4][5]
Sources:
[1]: FDA Orange Book - Lipitor Patents
[2]: DrugPatentWatch.com - Lipitor Patent Expiry
[3]: IMS Health (now IQVIA) Reports, 2012-2014
[4]: FTC Generic Competition Report, 2013
[5]: Pfizer Annual Reports, 2011-2013